Stanley Bergman - Henry Schein Executive Chairman and CEO
| HSIC Stock | USD 76.84 1.76 2.34% |
Chairman
Mr. Stanley M. Bergman serves as Chairman of the Board, Chief Executive Officer of the Company. He was with the Company since 1980, including as Chairman and Chief Executive Officer since 1989 and as a director since 1982. He is also a member of our Executive Management Committee. Mr. Bergman held the position of President of the Company from 1989 to 2005. Mr. Bergman held the position of Executive Vice President from 1985 to 1989 and Vice President of Finance and Administration from 1980 to 1985. Mr. Bergman brings to the Companys Board of Directors management and leadership experience. Mr. Bergman is a wellknown, highly regarded leader in the global health care industry. He has expansive knowledge of the health care industry and macroeconomic global conditions, maintains strategic relationships with chief executives and other senior management in the health care industry throughout the world and brings a unique and valuable perspective to the Board of Directors. During his tenure, Mr. Bergman has led the Company from sales of 600 million in 1995 to 12.5 billion in 2017. Mr. Bergman serves as a board member or advisor for numerous institutions, including New York University College of Dentistry, the University of Pennsylvania School of Dental Medicine, the Columbia University Medical Center, Hebrew University, Tel Aviv University, the University of the Witwatersrand Fund, the World Economic Forums Health Care Governors and the Business Council for International Understanding. Mr. Bergman is also a member of the boards of numerous charitable organizations and active with philanthropic causes and social responsibility activities. Mr. Bergman is a Certified Public Accountant. since 2005.
| Age | 74 |
| Tenure | 19 years |
| Address | 135 Duryea Road, Melville, NY, United States, 11747 |
| Phone | 631 843 5500 |
| Web | https://www.henryschein.com |
Stanley Bergman Latest Insider Activity
Tracking and analyzing the buying and selling activities of Stanley Bergman against Henry Schein stock is an integral part of due diligence when investing in Henry Schein. Stanley Bergman insider activity provides valuable insight into whether Henry Schein is net buyers or sellers over its current business cycle. Note, Henry Schein insiders must abide by specific rules, including filing SEC forms every time they buy or sell Henry Schein'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Stanley Bergman over two months ago Disposition of 634 shares by Stanley Bergman of Henry Schein subject to Rule 16b-3 | ||
Stanley Bergman over two months ago Disposition of 14080 shares by Stanley Bergman of Henry Schein subject to Rule 16b-3 | ||
Stanley Bergman over six months ago Disposition of 475 shares by Stanley Bergman of Henry Schein subject to Rule 16b-3 |
Henry Schein Management Efficiency
The company has return on total asset (ROA) of 0.0388 % which means that it generated a profit of $0.0388 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0633 %, meaning that it created $0.0633 on every $100 dollars invested by stockholders. Henry Schein's management efficiency ratios could be used to measure how well Henry Schein manages its routine affairs as well as how well it operates its assets and liabilities. As of November 26, 2024, Return On Tangible Assets is expected to decline to 0.07. In addition to that, Return On Capital Employed is expected to decline to 0.10. At present, Henry Schein's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 219.4 M, whereas Total Current Assets are forecasted to decline to about 2.4 B.Similar Executives
| Found 5 records | CHAIRMAN Age | ||
| Robert Sledd | Owens Minor | 67 | |
| Gregory Kenny | Cardinal Health | 67 | |
| Edward Mueller | McKesson | 73 | |
| Thomas Sandgaard | Zynex Inc | 65 | |
| Mark Beck | Owens Minor | 55 | |
Management Performance
| Return On Equity | 0.0633 | ||||
| Return On Asset | 0.0388 |
Henry Schein Leadership Team
Elected by the shareholders, the Henry Schein's board of directors comprises two types of representatives: Henry Schein inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Henry. The board's role is to monitor Henry Schein's management team and ensure that shareholders' interests are well served. Henry Schein's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Henry Schein's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Ettinger, Senior Vice President - Corporate and Legal Affairs, Secretary | ||
| Walter Siegel, Senior Vice President General Counsel | ||
| Graham Stanley, VP Officer | ||
| James CPA, President | ||
| Steven Paladino, CFO, Executive VP and Executive Director | ||
| Stanley Bergman, Executive Chairman and CEO | ||
| Ronald South, Senior CFO | ||
| Stanley CPA, Executive CEO | ||
| Olga Timoshkina, Chief Finance | ||
| Lorelei McGlynn, Senior Officer | ||
| Gerard Meuchner, Chief VP | ||
| Christine Sheehy, Senior Officer | ||
| Mark Mlotek, Chief Strategic Officer, Executive VP and Director | ||
| Christopher Pendergast, Senior Vice President CTO | ||
| Bradford Connett, Chief Group | ||
| Ann Gothard, Vice Relations | ||
| James Breslawski, President, Executive Director and CEO of Global Dental Group |
Henry Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Henry Schein a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0633 | ||||
| Return On Asset | 0.0388 | ||||
| Profit Margin | 0.03 % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 12.23 B | ||||
| Shares Outstanding | 124.68 M | ||||
| Shares Owned By Insiders | 0.90 % | ||||
| Shares Owned By Institutions | 99.10 % | ||||
| Number Of Shares Shorted | 6.8 M | ||||
| Price To Earning | 17.39 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Henry Schein offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Henry Schein's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Henry Schein Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Henry Schein Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Henry Schein. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For information on how to trade Henry Stock refer to our How to Trade Henry Stock guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Henry Schein. If investors know Henry will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Henry Schein listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.26) | Earnings Share 2.44 | Revenue Per Share 97.561 | Quarterly Revenue Growth 0.004 | Return On Assets 0.0388 |
The market value of Henry Schein is measured differently than its book value, which is the value of Henry that is recorded on the company's balance sheet. Investors also form their own opinion of Henry Schein's value that differs from its market value or its book value, called intrinsic value, which is Henry Schein's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Henry Schein's market value can be influenced by many factors that don't directly affect Henry Schein's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Henry Schein's value and its price as these two are different measures arrived at by different means. Investors typically determine if Henry Schein is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Henry Schein's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.